When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Ovarian cancer

Última revisão: 25 Mar 2025
Última atualização: 12 Mar 2025

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • pelvic mass
  • ascites
  • pleural effusion
Detalhes completos

Outros fatores diagnósticos

  • gastrointestinal symptoms
  • urinary urgency or frequency
  • symptom duration >3 months
  • abdominal distention
  • pelvic/abdominal pain or pressure
Detalhes completos

Fatores de risco

  • genetic mutations associated with hereditary ovarian cancer
  • increasing age
  • family history of ovarian cancer, breast cancer, colorectal cancer, and/or endometrial cancer
  • never used combined oral contraceptives
  • nulliparity
  • obesity
  • hormone therapy
  • endometriosis
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • pelvic ultrasound
  • CA-125
  • histopathology
Detalhes completos

Investigações a serem consideradas

  • genetic testing
  • PET, PET-CT, or PET/MRI
  • MRI
  • CT scan
  • biomarker tests
Detalhes completos

Algoritmo de tratamento

AGUDA

surgical candidate, intraoperative histology confirmed disease

poor surgical candidate, biopsy confirmed disease

CONTÍNUA

platinum-sensitive recurrent disease

platinum-resistant recurrent or refractory disease

Colaboradores

Autores

Sareena Singh, MD

Gynecologic Oncologist

Aultman Medical Group

Northeast Ohio Medical University

Canton

OH

Declarações

SS declares that she has no competing interests.

Agradecimentos

Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.

Declarações

JCC and AEA declare that they have no competing interests.

Revisores

Michael P. Hopkins, MD, MEd

Chairman

Obstetrics and Gynecology

Northeast Ohio Universities of Medicine (NEOMED)

Rootstown

OH

Declarações

MPH declares that he has no competing interests.

Ritu Salani, MD

Gynecologic Oncology Fellow

Johns Hopkins Medical Institutions

Baltimore

MD

Declarações

RS declares that she has no competing interests.

Susan A. Davidson, MD

Associate Professor

Chief, Gynecologic Oncology

Department of Obstetrics & Gynecology (UCD)

University of Colorado Cancer Center

Aurora

CO

Declarações

SAD declares that she has no competing interests.

Khadra Galaal, MBChB, MPH, MRCOG

Consultant Gynaecological Oncologist

Northern Gynaecological Oncology Centre

Queen Elizabeth Hospital

Gateshead

UK

Declarações

KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.

Jill Tseng, MD

Assistant Clinical Professor of Gynecologic Oncology

University of California, Irvine

Orange

CA

Declarações

JT declares that she has no competing interests.

  • Ovarian cancer images
  • Diagnósticos diferenciais

    • Irritable bowel syndrome (IBS)
    • Metastases to the ovary
    • Endometriosis
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
    • Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Ovarian cancer: what is it?

    Ovarian cancer: what treatments work?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal